Daklinza FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 25, 2019.
FDA Approved: Yes (Discontinued) (First approved July 24, 2015)
Brand name: Daklinza
Generic name: daclatasvir
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: Hepatitis C
Marketing Status: Discontinued
Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.
Development timeline for Daklinza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.